ProCE Banner Activity

Considerations for Managing Advanced Urothelial Cancer With Novel Therapies

Clinical Thought

The treatment landscape for advanced urothelial cancer is rapidly evolving and expanding. Identifying optimal therapies is key to optimizing patient outcomes. Read this commentary on important considerations for managing patients with advanced urothelial cancer using the most recent therapeutic advances available for these patients.

Released: January 04, 2022

Expiration: January 03, 2023



Arjun Balar

Arjun Balar, MD

Associate Professor of Medicine
Division of Hematology/Oncology
NYU Langone Health
New York, New York


This activity is supported by an educational grant from Astellas and Seagen Inc.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses


Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.


Clinical Thought


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.